Related Experiment Video
Updated: Jun 17, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?
1Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany. strassburg.christian@mh-hannover.de
Abstract:
Gilbert's syndrome is characterized by mild unconjugated nonhemolytic hyperbilirubinemia, without hepatic inflammation, fibrosis, chronic liver disease, or liver failure. It is readily diagnosed by genetic variants of the UGT1A1 gene, mainly UGT1A1*28, and is also associated with abnormalities of hepatobiliary transport and additional UGT1A gene variants. Apart from representing a potential risk factor in irinotecan and protease inhibitor therapy, it appears to exert protective effects in Hodgkin's lymphoma and cardiovascular disease. Gilbert's syndrome is part of a continuous spectrum of altered glucuronidation that extends to fatal Crigler-najjar disease. The complexity hidden behind this pharmacogenetic abnormality is of profound significance for drug development and therapy.
Related Concept Videos
Jaundice
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pleiotropy
Pharmacogenomics: Identification of New Drug Targets
